The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Steven M. Opal

Alpert Medical School of Brown University


Rhode Island



Name/email consistency: high



  • Alpert Medical School of Brown University, Providence, Rhode Island, USA. 2013
  • The Warren Alpert School of Medicine of Brown University, BioMed Center, Providence, RI 02912, USA. 2009 - 2011
  • Infectious Disease Research Laboratory, Memorial Hospital of Rhode Island, Pawtucket, RI 02860, USA. 2005 - 2011
  • Department of Medicine, Infectious Disease Division, Memorial Hospital of RI, The Warren Alpert Medical School of Brown University, USA. 2000 - 2009
  • Infectious Disease Division, Brown University School of Medicine, Providence, Rhode Island, USA. 1998 - 2007
  • Memorial Hospital of Rhode Island, Brown Medical School, Providence, Rhode Island 02860, USA. 2005
  • Brown University School of Medicine, Povidence, USA. 1999 - 2003
  • Infectious Disease Division and Department of Pathology, Memorial Hospital of Rhode Island and Brown University School of Medicine, Providence 02860, USA. 2003


  1. Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. Opal, S.M., Laterre, P.F., Francois, B., LaRosa, S.P., Angus, D.C., Mira, J.P., Wittebole, X., Dugernier, T., Perrotin, D., Tidswell, M., Jauregui, L., Krell, K., Pachl, J., Takahashi, T., Peckelsen, C., Cordasco, E., Chang, C.S., Oeyen, S., Aikawa, N., Maruyama, T., Schein, R., Kalil, A.C., Van Nuffelen, M., Lynn, M., Rossignol, D.P., Gogate, J., Roberts, M.B., Wheeler, J.L., Vincent, J.L. JAMA (2013) [Pubmed]
  2. The evolution of the understanding of sepsis, infection, and the host response: a brief history. Opal, S.M. Crit. Care. Nurs. Clin. North. Am (2011) [Pubmed]
  3. Inter-α inhibitor proteins: a novel therapeutic strategy for experimental anthrax infection. Opal, S.M., Lim, Y.P., Cristofaro, P., Artenstein, A.W., Kessimian, N., Delsesto, D., Parejo, N., Palardy, J.E., Siryaporn, E. Shock (2011) [Pubmed]
  4. Endotoxins and other sepsis triggers. Opal, S.M. Contrib. Nephrol (2010) [Pubmed]
  5. Year in review 2008: Critical Care--sepsis. Opal, S.M., LaRosa, S.P. Crit. Care (2009) [Pubmed]
  6. Translational research in the development of novel sepsis therapeutics: logical deductive reasoning or mission impossible?. Opal, S.M., Patrozou, E. Crit. Care Med. (2009) [Pubmed]
  7. Coming soon to an ICU near you: severe pandemic influenza in ICU patients in Spain. Opal, S.M. Crit. Care (2009) [Pubmed]
  8. The evolution of the understanding of sepsis, infection, and the host response: a brief history. Opal, S.M. Crit. Care. Clin (2009) [Pubmed]
  9. The host response to endotoxin, antilipopolysaccharide strategies, and the management of severe sepsis. Opal, S.M. Int. J. Med. Microbiol. (2007) [Pubmed]
  10. Can we RESOLVE the treatment of sepsis?. Opal, S.M. Lancet (2007) [Pubmed]
  11. Endotoxin and cytokine detection systems as biomarkers for sepsis-induced renal injury. Opal, S.M. Contrib. Nephrol (2007) [Pubmed]
  12. Communal living by bacteria and the pathogenesis of urinary tract infections. Opal, S.M. PLoS Med. (2007) [Pubmed]
  13. Inter-alpha-inhibitor proteins are endogenous furin inhibitors and provide protection against experimental anthrax intoxication. Opal, S.M., Artenstein, A.W., Cristofaro, P.A., Jhung, J.W., Palardy, J.E., Parejo, N.A., Lim, Y.P. Infect. Immun. (2005) [Pubmed]
  14. The immunopathogenesis of sepsis in elderly patients. Opal, S.M., Girard, T.D., Ely, E.W. Clin. Infect. Dis. (2005) [Pubmed]
  15. Active immunization with a detoxified endotoxin vaccine protects against lethal polymicrobial sepsis: its use with CpG adjuvant and potential mechanisms. Opal, S.M., Palardy, J.E., Chen, W.H., Parejo, N.A., Bhattacharjee, A.K., Cross, A.S. J. Infect. Dis. (2005) [Pubmed]
  16. The activity of pathway-selective estrogen receptor ligands in experimental septic shock. Opal, S.M., Palardy, J.E., Cristofaro, P., Parejo, N., Jhung, J.W., Keith, J.C., Chippari, S., Caggiano, T.J., Steffan, R.J., Chadwick, C.C., Harnish, D.C. Shock (2005) [Pubmed]
  17. The use of immunocompromised animals as models for human septic shock. Opal, S.M., Cross, A.S. Shock (2005) [Pubmed]
  18. The nexus between systemic inflammation and disordered coagulation in sepsis. Opal, S.M. J. Endotoxin Res. (2004) [Pubmed]
  19. Orally administered recombinant human interleukin-11 is protective in experimental neutropenic sepsis. Opal, S.M., Keith, J.C., Jhung, J., Palardy, J.E., Parejo, N., Marchese, E., Maganti, V. J. Infect. Dis. (2003) [Pubmed]
  20. Bench-to-bedside review: functional relationships between coagulation and the innate immune response and their respective roles in the pathogenesis of sepsis. Opal, S.M., Esmon, C.T. Crit. Care (2003) [Pubmed]
  21. Effect of anti-CD14 monoclonal antibody on clearance of Escherichia coli bacteremia and endotoxemia. Opal, S.M., Palardy, J.E., Parejo, N., Jasman, R.L. Crit. Care Med. (2003) [Pubmed]
  22. Systemic host responses in severe sepsis analyzed by causative microorganism and treatment effects of drotrecogin alfa (activated). Opal, S.M., Garber, G.E., LaRosa, S.P., Maki, D.G., Freebairn, R.C., Kinasewitz, G.T., Dhainaut, J.F., Yan, S.B., Williams, M.D., Graham, D.E., Nelson, D.R., Levy, H., Bernard, G.R. Clin. Infect. Dis. (2003) [Pubmed]
  23. Clinical trial design and outcomes in patients with severe sepsis. Opal, S.M. Shock (2003) [Pubmed]
  24. Severe sepsis and septic shock: defining the clinical problem. Opal, S.M. Scand. J. Infect. Dis. (2003) [Pubmed]
  25. Interactions between coagulation and inflammation. Opal, S.M. Scand. J. Infect. Dis. (2003) [Pubmed]
  26. Bench-to-bedside review: Toll-like receptors and their role in septic shock. Opal, S.M., Huber, C.E. Crit. Care (2002) [Pubmed]
  27. Antithrombin, heparin, and heparan sulfate. Opal, S.M., Kessler, C.M., Roemisch, J., Knaub, S. Crit. Care Med. (2002) [Pubmed]
  28. The clinical relevance of endotoxin in human sepsis: a critical analysis. Opal, S.M. J. Endotoxin Res. (2002) [Pubmed]
  29. The activity of tissue factor pathway inhibitor in experimental models of superantigen-induced shock and polymicrobial intra-abdominal sepsis. Opal, S.M., Palardy, J.E., Parejo, N.A., Creasey, A.A. Crit. Care Med. (2001) [Pubmed]
  30. Lipopolyamines as a therapeutic strategy in experimental Gram-negative bacterial sepsis. Opal, S.M., Palardy, J.E., Parejo, N., Morrison, D.C. J. Endotoxin Res. (2001) [Pubmed]
  31. Clinical impact of novel anticoagulation strategies in sepsis. Opal, S.M. Curr. Opin. Crit. Care (2001) [Pubmed]
  32. Recombinant human interleukin-11 has anti-inflammatory actions yet does not exacerbate systemic Listeria infection. Opal, S.M., Keith, J.C., Palardy, J.E., Parejo, N. J. Infect. Dis. (2000) [Pubmed]
  33. Anti-inflammatory cytokines. Opal, S.M., DePalo, V.A. Chest (2000) [Pubmed]
  34. Therapeutic rationale for antithrombin III in sepsis. Opal, S.M. Crit. Care Med. (2000) [Pubmed]
  35. Phylogenetic and functional relationships between coagulation and the innate immune response. Opal, S.M. Crit. Care Med. (2000) [Pubmed]
  36. Clinical gram-positive sepsis: does it fundamentally differ from gram-negative bacterial sepsis?. Opal, S.M., Cohen, J. Crit. Care Med. (1999) [Pubmed]
  37. Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock. Opal, S.M., Scannon, P.J., Vincent, J.L., White, M., Carroll, S.F., Palardy, J.E., Parejo, N.A., Pribble, J.P., Lemke, J.H. J. Infect. Dis. (1999) [Pubmed]
  38. Antiendotoxin strategies for the prevention and treatment of septic shock. New approaches and future directions. Opal, S.M., Yu, R.L. Drugs (1998) [Pubmed]
WikiGenes - Universities